

NEW STRATEGIES IN DIAGNOSIS AND TREATMENT: FROM BENCH TO BED

 JUNE 12\13, 2015

FINAL PROGRAMME

Friday, 12 June 2015	
8.00-9.00	Registration
9.00-9.30	Welcome Address/Opening ceremony Chairs: S. Cicėnas (Vilnius, Lithuania) <i>Minister of health of the Republic of Lithuania (Vilnius, Lithuania)</i> <i>Rector of Vilnius University (Vilnius, Lithuania)</i> <i>Dean of the Faculty of Medicine Vilnius University (Vilnius, Lithuania)</i> <i>Director of the Nacional Cancer Institute (Vilnius, Lithuania)</i>
9.30 – 11.00	SESSION I Chairs: J. Niklinski (Bialystok, Poland), K. Sužiedėlis (Vilnius, Lithuania)
9.30-11.00	Bialystok Medical Academy – Research Group (Bialystok, Poland) Chairs: Prof. Jacek Niklinski, Prof. Lech Chyczewski <ul style="list-style-type: none"> • Immune system and lung cancer: friends or foes? <i>M. Moniuszko</i> • Science fiction or science reality - microRNA replacement therapy <i>Anna Rusek</i> • The role of transcription factor Sox2 in cancer biology <i>A. Eljaszewicz</i> • Recent guidelines for the diagnosis of non-small cell lung cancer- diagnostic challenges and problems <i>J. Reszec</i> • Metabolomic profiling of non-small cell lung cancer <i>J. Kisluk</i>
11.00 - 11.30	Lung cancer in women and never smokers <i>S. Novello (Turin, Italy)</i>
11.30 - 12.00	Coffee break
12.00 –13.00	AstraZeneca Satellite Symposium Chair: S. Cicėnas (<i>Vilnius, Lithuania</i>)
13.00-14.00	Lunch
14.00 – 16.40	Scientific session II Chairs: R. Pirker (Vienna, Austria), E. Danila (Vilnius, Lithuania).
14.00-14.40	Bevacizumab in treatment of NSCLC: preferred chemo partners <i>F. De Marinis (Milan, Italy)</i>
14.40-15.00	Lung Cancer Screening – Radiological Opportunities and Challenges <i>S. Sudarski (Mannheim, Germany)</i>
15.00-15.20	Tobacco control strategies <i>M. Neuberger (Vienna, Austria)</i>
15.20-15.40	Lung cancer screening by spiral CT <i>M. Silva (Milano, Italy)</i>
15.40-16.00	Biomarkers for chemotherapy in NSCLC <i>J.B. Soerensen (Copenhagen, Denmark)</i>
16.00-16.20	Adjuvant therapy of completely resected NSCLC: current status and perspectives <i>R. Pirker (Vienna, Austria)</i>
16.20-16.40	The application of electronic odour identification system in disease diagnosis: possibilities and

	limitations <i>A. Šetkus (Vilnius, Lithuania)</i>
16.40 – 17.00	Coffee break
17.00 – 19.00	Scientific session III Chairs: Ch. Manegold (Mannheim, Germany), L. Pilz (Mannheim, Germany)
17.00-17.40	Mechanisms of resistance to EGFR TKI and treatment strategies <i>F. De Marinis (Milan, Italy)</i>
17.40-18.00	Necitumumab and ramucirumab: Promising monoclonal antibodies in NSCLC <i>Ch. Manegold (Mannheim, Germany)</i>
18.00– 18.20	New concepts for study design in lung cancer <i>L. Pilz (Mannheim, Germany)</i>
18.20-18.40	Modern trends in surgery and multimodality treatment of thymic tumours <i>O. Pikin (Moscow, Russian Federation)</i>
18.40-19.00	Molecular testing - expanding therapeutic options for NSCLC patients after introducing of afatinib <i>P. Krawczyk (Lublin, Poland)</i>
19.00 – 19.20	Treatment of NSLC after progression <i>O.-T. Brustugum (Oslo, Norway)</i>
19:30	Dinner (hotel restaurant "Sezonai" ground floor)
Saturday, 13 June 2015	
8.00-9.00	Registration
9.00- 10.00	Scientific session IV - Case reports Chairs: O. Pikin (Moscow, Russian Federation), E. Sigal (Kazan, Russian Federation)
9.00-9.20	Combined and radical treatment for initially inoperable NSCLC <i>A. Akopov (Petersburg, Russian Federation)</i>
9.20 – 9.40	Making a diagnosis: the challenging case from pathologist <i>A. Šimbelytė (Vilnius, Lithuania)</i>
9.40 – 10.00	Pharyngo-gastro anastomosis after upper part of esophageal cancer resections <i>M. Burmistrov, A. Rudik (Kazan, Russian Federation)</i>
10.00-10.20	Coffee Break
10.20- 11:20	Scientific session V - Case reports Chairs: M. Burmistrov (Kazan, Russian Federation), S. Cicėnas (Vilnius, Lithuania), V. Zharkov (Minsk, Belarus)
10.20-10.40	International VTE Clinical Guidelines in Cancer <i>D. Inčiūra (Kaunas, Lithuania)</i>
10.40-11.00	Radical treatment of lung cancer patient with massive invasion of left atrium <i>V. Zharkov, S. Yeskov (Minsk, Belarus)</i>
11.00-11.20	Long term survival in metastatic NSCLC <i>D. Vaitiekus (Kaunas, Lithuania)</i>
11.20- 11.40	Closing remarks Chairs: Ch. Manegold (Mannheim, Germany), J. Niklinski (Bialystok, Poland), S. Cicėnas (Vilnius, Lithuania)